Keros Therapeutics (KROS) Competitors $14.49 +0.24 (+1.68%) Closing price 04:00 PM EasternExtended Trading$14.48 -0.01 (-0.03%) As of 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KROS vs. TWST, RXRX, GMTX, AGIO, DNLI, BEAM, VCEL, KNSA, CGON, and BLTEShould you be buying Keros Therapeutics stock or one of its competitors? The main competitors of Keros Therapeutics include Twist Bioscience (TWST), Recursion Pharmaceuticals (RXRX), Gemini Therapeutics (GMTX), Agios Pharmaceuticals (AGIO), Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Vericel (VCEL), Kiniksa Pharmaceuticals International (KNSA), CG Oncology (CGON), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry. Keros Therapeutics vs. Its Competitors Twist Bioscience Recursion Pharmaceuticals Gemini Therapeutics Agios Pharmaceuticals Denali Therapeutics Beam Therapeutics Vericel Kiniksa Pharmaceuticals International CG Oncology Belite Bio Keros Therapeutics (NASDAQ:KROS) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability. Do institutionals & insiders hold more shares of KROS or TWST? 71.6% of Keros Therapeutics shares are held by institutional investors. 20.6% of Keros Therapeutics shares are held by company insiders. Comparatively, 3.0% of Twist Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, KROS or TWST? Keros Therapeutics has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 2.41, suggesting that its share price is 141% more volatile than the S&P 500. Does the media prefer KROS or TWST? In the previous week, Twist Bioscience had 4 more articles in the media than Keros Therapeutics. MarketBeat recorded 5 mentions for Twist Bioscience and 1 mentions for Keros Therapeutics. Keros Therapeutics' average media sentiment score of 0.94 beat Twist Bioscience's score of 0.56 indicating that Keros Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Keros Therapeutics Positive Twist Bioscience Positive Do analysts recommend KROS or TWST? Keros Therapeutics presently has a consensus target price of $30.56, suggesting a potential upside of 110.87%. Twist Bioscience has a consensus target price of $50.40, suggesting a potential upside of 37.37%. Given Keros Therapeutics' higher probable upside, equities analysts clearly believe Keros Therapeutics is more favorable than Twist Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Keros Therapeutics 0 Sell rating(s) 7 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.50Twist Bioscience 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70 Which has stronger earnings & valuation, KROS or TWST? Keros Therapeutics has higher earnings, but lower revenue than Twist Bioscience. Keros Therapeutics is trading at a lower price-to-earnings ratio than Twist Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKeros Therapeutics$214.71M2.74-$187.35M-$0.18-80.50Twist Bioscience$347.68M6.32-$208.73M-$3.25-11.29 Is KROS or TWST more profitable? Keros Therapeutics has a net margin of 1.96% compared to Twist Bioscience's net margin of -54.98%. Keros Therapeutics' return on equity of 0.75% beat Twist Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Keros Therapeutics1.96% 0.75% 0.69% Twist Bioscience -54.98%-33.48%-25.34% SummaryKeros Therapeutics beats Twist Bioscience on 9 of the 16 factors compared between the two stocks. Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KROS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KROS vs. The Competition Export to ExcelMetricKeros TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$588.51M$2.93B$5.57B$9.31BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-80.5020.4928.6119.73Price / Sales2.74267.08411.31174.27Price / CashN/A43.1536.0257.96Price / Book1.037.768.235.67Net Income-$187.35M-$55.11M$3.23B$257.79M7 Day Performance1.19%0.95%-0.01%0.52%1 Month Performance6.08%8.44%5.60%8.84%1 Year Performance-72.23%-2.38%26.54%14.18% Keros Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KROSKeros Therapeutics2.0758 of 5 stars$14.49+1.7%$30.56+110.9%-72.1%$588.51M$214.71M-80.50100Positive NewsTWSTTwist Bioscience4.1794 of 5 stars$38.81-0.8%$50.40+29.9%-35.2%$2.32B$347.68M-11.93990RXRXRecursion Pharmaceuticals1.8109 of 5 stars$5.73+2.4%$7.00+22.3%-36.3%$2.32B$58.84M-3.23400GMTXGemini TherapeuticsN/A$52.97-0.8%N/A+22.4%$2.30BN/A-52.9730News CoverageAGIOAgios Pharmaceuticals4.3771 of 5 stars$38.99-0.2%$58.60+50.3%-16.5%$2.25B$36.50M3.46390News CoverageAnalyst RevisionDNLIDenali Therapeutics4.6765 of 5 stars$15.05+0.3%$33.71+124.1%-39.3%$2.19B$330.53M-5.63430Positive NewsBEAMBeam Therapeutics2.0936 of 5 stars$21.56+0.5%$48.75+126.1%-23.6%$2.17B$63.58M-4.67510VCELVericel3.6942 of 5 stars$42.37+2.1%$61.14+44.3%-25.6%$2.13B$237.22M1,412.64300News CoveragePositive NewsKNSAKiniksa Pharmaceuticals International3.3683 of 5 stars$28.88+0.3%$39.33+36.2%+30.0%$2.11B$481.17M-115.52220Upcoming EarningsCGONCG Oncology2.7542 of 5 stars$27.29+0.9%$56.80+108.1%-31.9%$2.08B$662K-18.0861News CoveragePositive NewsAnalyst ForecastBLTEBelite Bio1.9921 of 5 stars$62.39-2.8%$96.67+54.9%+29.2%$1.99BN/A-45.8810 Related Companies and Tools Related Companies Twist Bioscience Alternatives Recursion Pharmaceuticals Alternatives Gemini Therapeutics Alternatives Agios Pharmaceuticals Alternatives Denali Therapeutics Alternatives Beam Therapeutics Alternatives Vericel Alternatives Kiniksa Pharmaceuticals International Alternatives CG Oncology Alternatives Belite Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KROS) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
